Business
Alivio Adds Dr Harry Leider to Board of Directors
Alivio Adds Dr Harry Leider to Board of Directors.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3670A\n PureTech Health PLC\n 29 September 2020\n \n \n \n \n 29 September 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity \n \n \n Alivio Therapeutics \n \n \n Appoints Harry Leider, MD, to Board of Directors\n \n \n \n \n \n \n Dr Leider, chief medical officer at Gelesis and formerly Walgreens, brings strong \n \n \n medical background and experience in clinical development to the board\n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Alivio Therapeutics, \n today announced the addition of Harry Leider, MD, MBA, to its Board of Directors. Dr Leider's extensive medical background and leadership experience in developing products leveraging proprietary technology will be important assets as Alivio advances its pipeline to potentially treat a range of disruptive diseases with broad unmet need.\n \n \n \n \n \n \n As chief medical officer at Gelesis, Dr Leider is involved in the clinical testing of all Gelesis' pipeline and in-line products. He played a role in the FDA submission and clearance leading to the commercialisation of Plenity®, an orally-administered, non-stimulant, non-systemic aid for weight management in \n adults with a Body Mass Index, or BMI, of 25-40 kg/m2, when used in conjunction with diet and exercise\n . Prior to joining Gelesis, he served as global chief medical officer and group vice president at Walgreens, where he provided executive leadership for all clinical programme development, quality assessment, health outcomes research, health analytics and clinical reporting activities across the enterprise.\n \n \n \n \n \n The full text of the announcement from Alivio Therapeutics is as follows:\n \n \n \n \n \n Alivio Therapeutics Appoints Harry Leider, MD to Board of Directors\n \n \n \n \n \n Dr Leider, chief medical officer at Gelesis and formerly Walgreens, brings strong \n \n \n medical background and experience in clinical development to the board\n \n \n \n \n \n \n BOSTON, September 29, 2020\n \n - Alivio Therapeutics, a biotechnology company...